share_log

SVB Leerink Maintains Outperform on Beam Therapeutics, Raises Price Target to $121

Benzinga Real-time News ·  May 9, 2022 13:14

SVB Leerink analyst Rick Bienkowski maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $118 to $121.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment